|
Primary treatment (n=186)
|
| Topical mitomycin-C |
2 (1) |
| Wide excision biopsy |
146 (78) |
| Orbital exenteration |
22 (12) |
| Neoadjuvant systemic chemotherapy |
16 (9) |
| |
|
|
Secondary treatment (n=175)
|
| Topical mitomycin-C |
3 (2) |
| Cryotherapy |
6 (3) |
| Wide excision biopsy |
31 (18) |
| Orbital exenteration |
10 (6) |
| |
|
|
Adjuvant treatment (n=175)
|
| Systemic chemotherapy |
9 (5) |
| External beam radiotherapy |
31 (18) |
| Radical neck dissection |
13 (7) |
| Primary/secondary orbital exenteration (n=186) |
37 (20) |
| Tumor recurrence (n=175) |
42 (24) |
| Time interval between primary treatment and tumor recurrence (months), mean (median, range) |
19 (13; <1–125) |
| Follow-up duration (months), mean (median, range) |
29 (20; <1–208) |
| |
|
|
Final outcome at last follow-up (n=181)
|
| Alive and well |
136 (75) |
| Regional lymph node metastasis |
41 (23) |
| Systemic metastasis |
26 (14) |
| Death due to systemic metastasis |
19 (10) |
| Death due to unrelated cause |
4 (2) |
